Arno Therapeutics, Inc. (ARNI)

Arno Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011
Period Ending	Sep 30, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011
Selling, General & Admin	4.61	4.76	6.25	3.46	2.3	1.96
Research & Development	6.45	8.65	14.84	13.48	8.54	5.69
Operating Expenses	11.06	13.41	21.09	16.94	10.84	7.65
Operating Income	-11.06	-13.41	-21.09	-16.94	-10.84	-7.65
Interest Expense	-0.04	-0.03	-0	-18.57	-6.36	-
Interest & Investment Income	0	0.01	0.04	0.02	0.01	0.03
Other Non Operating Income (Expenses)	-2.59	1.92	29.22	-4.17	2.8	-0.29
EBT Excluding Unusual Items	-13.7	-11.51	8.17	-39.66	-14.39	-7.91
Other Unusual Items	-	-	-0.4	-	-	-
Pretax Income	-13.7	-11.51	7.77	-39.66	-14.39	-7.91
Net Income	-13.7	-11.51	7.77	-39.66	-14.39	-7.91
Preferred Dividends & Other Adjustments	-	-	-	-	-	0.08
Net Income to Common	-13.7	-11.51	7.77	-39.66	-14.39	-7.99
Shares Outstanding (Basic)	36	20	20	8	5	4
Shares Outstanding (Diluted)	36	20	25	8	5	4
Shares Change (YoY)	78.21%	-17.74%	230.09%	65.54%	5.24%	69.09%
EPS (Basic)	-0.38	-0.56	0.38	-5.28	-3.17	-1.85
EPS (Diluted)	-0.38	-0.56	0.31	-5.28	-3.17	-1.85
Free Cash Flow	-7.62	-9.97	-18.83	-14.24	-9.42	-6.86
Free Cash Flow Per Share	-0.21	-0.49	-0.76	-1.90	-2.08	-1.59
EBITDA	-11.06	-13.4	-21.08	-16.93	-10.82	-7.64
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01	0.01
EBIT	-11.06	-13.41	-21.09	-16.94	-10.84	-7.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.